TARRYTOWN, N.Y., Oct. 27, 2020 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management
participation as follows:
- Credit Suisse 29th Annual Virtual Healthcare
Conference at 8:45 a.m. EST
on Monday, November 9, 2020
- Cowen Virtual Presentation Series – 2020 IO Next Summit at 1:15
p.m. EST on Friday, November 13,
2020
- Jefferies Virtual London Healthcare Conference at 7:20 a.m. EST (12:20 p.m.
GMT) on Tuesday, November 17,
2020
The sessions may be accessed from the "Investors &
Media" page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations.
Replays of the webcasts will be archived on the Company's website
for at least 30 days.
About Regeneron
Regeneron (NASDAQ:
REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for over 30 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to eight FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
our laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, infectious
diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune®, which uses unique
genetically-humanized mice to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
Twitter.
Contact Information:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-announces-investor-conference-presentations-301161036.html
SOURCE Regeneron Pharmaceuticals, Inc.